ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DXRX Diaceutics Plc

103.00
0.00 (0.00%)
Last Updated: 08:00:07
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 103.00 102.00 104.00 103.00 103.00 103.00 0.00 08:00:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Testing Laboratories 19.5M 724k 0.0086 119.77 87.01M

Diaceutics PLC Presentation at Big Data Belfast

24/10/2019 7:01am

RNS Non-Regulatory


TIDMDXRX

Diaceutics PLC

24 October 2019

Diaceutics PLC

("Diaceutics" or the "Company")

Presentation at Big Data Belfast

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces that it will attend the Big Data Belfast conference as an invited speaker at the ICC Waterfront in Belfast on 24 October. Big Data Belfast is one of the leading data and technology events on the island of Ireland, driving thought leadership in one of the most exciting and expansive business clusters. This established conference has been running for seven years, featuring global data and analytics experts and best in class data driven organisations.

Derek Hosty, Head of Global Data at Diaceutics will deliver a presentation during the Artificial Intelligence and Machine Learning section of the conference entitled 'Using Big Data to make Better Decisions in Healthcare.' The presentation will be available on the Company's website from the end of the day and can be accessed via this link:

https://www.diaceutics.com/using-big-data-to-make-better-decisions-in-healthcare/

The Company's proprietary data offering combines diagnostic testing, claims and prescription data providing actionable insights for 115m+ patient records covering 47 deductive pathways in 35 global markets. Diaceutics' presentation will demonstrate how smart application of the Company's data analytics can significantly impact outcomes for patients in need of precision medicine therapies using a case study of metastatic lung cancer.

Enquiries:

 
 Diaceutics PLC                                                         www.diaceutics.com 
 Peter Keeling, Chief Executive                                            via Walbrook PR 
  Officer 
 Philip White, Chief Financial 
  Officer 
 
 Walbrook PR                         Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com 
 Anna Dunphy                                                      Mob: +44 (0)7876 741 001 
 Paul McManus                                                     Mob: +44 (0)7980 541 893 
 
 

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRABUBDGRBDBGCX

(END) Dow Jones Newswires

October 24, 2019 02:01 ET (06:01 GMT)

1 Year Diaceutics Chart

1 Year Diaceutics Chart

1 Month Diaceutics Chart

1 Month Diaceutics Chart

Your Recent History

Delayed Upgrade Clock